Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5730986 | 0.84 | CYP2D6 (0.34) | CYP2D6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL5730696 | 0.75 | CTSK (0.34) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL15922626 | 0.67 | ARG1 (0.41) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1359695 | 0.63 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30085352 | 0.63 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL16967366 | 0.63 | ARG1 (0.49) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL19617294 | 0.62 | ARG1 (0.31) | ARG1ARG2 | |
| SCHEMBL1234317 | 0.62 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL3675366 | 0.61 | ARG1 (0.54) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL3676543 | 0.61 | ARG1 (0.54) | ARG1ARG2CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651623-B1 | HEXAHYDRODIAZEPINONES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-7259160-B2 | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1651623-A4 | HEXAHYDRODIAZEPINONES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060211682-A1 | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | disclosed |
| EP-1651623-A2 | HEXAHYDRODIAZEPINONES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005011581-A2 | HEXAHYDRODIAZEPINONES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211682-A1 | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | ARG1 3955/4885ARG2 3469/4885CYP2D6 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.